Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-06-07
Tempus AI, Inc.
Tempus provides molecular diagnostics, clinical workflow software, and de-identified data and analytics products for physicians, health systems, and biopharma customers.
ai enterprise healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From Diagnostic Volume to Workflow Utility
The upside case is that a regulated diagnostics business matures into a broader clinical and biopharma operating layer with better mix and lower financing pressure. Recent launches and approvals help, but the story still hinges on proving durable economic conversion.

Analysis

Thesis
Tempus can turn each reimbursed diagnostic interaction into a compounding data and workflow asset; if recent assay approvals and Data & Applications momentum convert into multi-year clinical and biopharma contracts, it can grow from a genomics business with software upside into a larger precision-medicine operating system.
Last Economy Alignment
Cheaper cognition makes Tempus’s owned data, regulated diagnostics, and embedded clinical workflows more valuable; the main cap is regulation and data-rights governance, not software commoditization.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
This is still mainly a revenue-compounding case. Tempus already has real demand, but the upside depends on proving that diagnostics volume reliably feeds higher-margin data, workflow, and evidence products. I assume some multiple compression versus pure software hopes, partly offset by better mix, more regulated assets, and lower financing pressure as EBITDA improves.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is economic conversion, not product existence. Tempus has real products, real demand, and a credible data flywheel, but it still must prove that recent regulatory wins and workflow launches convert into durable, higher-margin revenue before privacy constraints, reimbursement friction, or EHR and lab competition cap it at a diagnostics-style multiple.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.56
They control regulated tests, governed patient data, and the workflow where doctors order and read results, so cheaper AI makes their data and software more useful. The danger is that privacy rules, reimbursement delays, or EHR-native agents stop them from turning that position into durable higher-margin revenue.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$66.53
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case